The company has applied for orphan drug status in the US and intends doing so for the EU. ReceptoPharm expects to present the clinical findings from the study by the end of September 2008.
Paul Reid, CEO of ReceptoPharm, said: “Completing this clinical trial is an important achievement for both Nutra Pharma and ReceptoPharm. Our next step is to compile, analyze and present the results from this trial to the medical community.”